The US FDA Approved Alnylam’s OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1

Alnylam Announces FDA Approval of OXLUMO™ Injection for PH1
Alnylam (ALNY) announced that the US FDA has approved its subcutaneous OXLUMO™ (lumasiran) injection, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Primary Hyperoxaluria Type 1 
PH1 is an ultra-rare genetic disease. It is . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.